This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A discussion of zuranolone in MDD: As data continues to be released what does the CORAL study say about the drug's future?

Ticker(s): SAGE

Who's the expert?

Institution: University of Pennsylvania

  • Professor of Psychiatry at the Perelman School of Medicine
  • Research interests include genetics, pharmacogenetics and medical treatment of addictions, mood disorders, schizophrenia, and epilepsy
  • The Berrettini Lab is currently studying single cell transcriptomics in neurons and glia as potential causative factors in risk for addictions, psychotic illnesses, and mood disorders.

Interview Questions
Q1.

Roughly how many patients with MDD do you currently manage?

Added By: c_admin
Q2.

What are your thoughts on the recent data from the CORAL study?

Added By: c_admin
Q3.

On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for zuranalone?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.